Supplementary Information
Primary amines protect against retinal degeneration in mouse models of retinopathies [3−(trifluoromethyl)−5,6−dihydro[1,2,4] (S)−4−oxo−4− [3−(trifluoromethyl)−5,6−dihydro[1,2,4] triazolo [4,3−a] . To purify the reaction products, crude reaction mixtures were injected onto a reverse phase C18 column (Phenomenex, 250 x 4.6, 5 µm) and retinoids were separated by a linear acetonitrile−water gradient with 0.05% TFA (80 -100% acetonitrile over 20 min at a flow rate of 1.5 ml/min). The presence of A2E was detected based on its characteristic UV/Vis absorbance spectrum. Fractions with peaks corresponding to products of interest were collected and analyzed by tandem mass spectrometry. Isotopically labeled A2E used for MS quantification was prepared as described above.
Mouse eye A2E purification and analysis. Two enucleated mouse eyes were homogenized in 1 ml of prechilled −20 o C acetonitrile with a kinematic Polytron homogenizer (PT 1200). The resulting sample was then homogenized in a glass−glass homogenizer, extracted twice with 1 ml of acetonitrile and centrifuged at 13,000g for 2 min. The supernatant was collected, transferred to a glass test tube, and dried down in a SpeedVac.
Prior to HPLC separation, the sample was dissolved in 0.2 ml of acetonitrile supplemented with 0.1% TFA and filtered through a Teflon syringe filter (National Scientific Company, Rockwood, TN). Extracted retinoids were separated on a C18 reverse−phase HPLC column (Agilent Zorbax Eclipse XBD C18, 5 µm, 4.6 x 150 mm) with a linear gradient of acetonitrile in water (80 -100%) and 0.1% TFA at a flow rate of 1.5 ml/min for 30 min. Elution of A2E was monitored at 435 nm.
Mass spectrometry and quantification of A2E. After mouse eye extracts were loaded on a C18 reverse−phase HPLC column (Agilent Zorbax Eclipse XBD C18, 5 µm, 4.6 x 150 mm), a linear gradient of acetonitrile in water (80 -100%) with 0.05% TFA run over 30 min at a flow rate of 1.5 ml/min was used to elute retinoids. Eluents were directed into a LXQ mass spectrometer through an APCI source. To achieve optimal sensitivity, the instrument was tuned first with synthetic A2E or an A2E−like standard. Deuterated A2E synthesized from commercially available D6−atRAL was used as an internal standard for quantification. Known amounts of an appropriate deuterated standard (10 -60 pmol) were added to each sample prior to homogenization.
The ratio between signals corresponding to the deuterated and endogenous retinoids was used for precise quantification of A2E. 
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Supplementary Figure 1 In vivo imaging of mouse retinas by OCT: grading retinopathy to assess the efficacy of primary amine drug pretreatment in protecting against bright light−induced and age−related retinal degeneration. Supplementary Figure 2 Effects of primary amines on LRAT and retinoid isomerization activities displayed by bovine RPE microsomes. Supplementary Figure 3 Effect of primary amines on 11−cis−retinal regeneration.
Supplementary Figure 4 Time−dependent effect of primary amine A20R on dark adaptation and light−induced degeneration after bright light exposure. Supplementary Figure 5 Effects of primary amine A22 Schiff base formation on atRAL metabolism and cytotoxicity in vitro. Supplementary Figure 6 Quantification of retinylidenes in mouse eye after administration of amine A20. Supplementary Figure 7 The spectra of condensation products between all−trans−retinal and 3−aminomethyl−5−methylhexanoic acid. Supplementary Figure 8 An example of A2E quantification in mouse retina.
Supplementary Figure 9
Effects of treatment with primary amine drugs on age−related retinal degeneration in Abca4 −/− Rdh8 −/− mice. Supplementary Figure 10 Effects of A20RS on retinal degeneration in rhodopsin−palmitoylation deficient and Rdh12 −/− mice. Supplementary Table 1 Primary amines tested for protection against light−dependant retinal degeneration in Abca4 −/− Rdh8 −/− mice. Supplementary Table 2 Distribution of SLO gray values after primary amine treatment of Abca4 −/− Rdh8 −/− mice for 3 months. Fig. 2 and Supplementary Fig. 3a) , most atRAL was efficiently cleared by enzymatic machinery (primary reduction to retinol by RDHs). However, the fraction of free all−trans−retinal that cannot be processed rapidly and persists in the retina represents a critical risk factor for retinal degeneration 
Supplementary
Rdh8
-/-mice were treated daily by gavage with either A20RS (2 mg/mouse), A20R (0.5 or 2 mg/mouse) or A22 (2 mg/mouse) and weekly with A24 (2 mg/mouse) for 3 months beginning at 1 month of age (see Fig. 6 , and Supplementary Fig. 9 ). The intensity of fundus autofluorescence in retinas of Abca4 
-/-mice was significantly less than that of vehicle-treated animals.
